Bioequivalence Study of Two MN-166 (Ibudilast) 50 mg Extended Release Tablet Formulations Compared With MN-166 (Ibudilast) 10mg Capsules in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2019
Price : $35 *
At a glance
- Drugs Ibudilast (Primary)
- Indications Asthma; Stroke complications
- Focus Pharmacokinetics
- Sponsors MediciNova
- 27 Nov 2018 Status changed from active, no longer recruiting to completed.
- 18 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 25 May 2018 New trial record